Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review
Authors:
- J. BryantJBJ. Bryant
- J. PicotJPJ. Picot
- L. BaxterLBL. Baxter
- G. LevittGLG. Levitt
- I. SullivanISI. Sullivan
- A. CleggACA. Clegg
- 1 September 2007
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (13) , 1959-1966
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic reviewHealth Technology Assessment, 2007
- Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic reviewBritish Journal of Cancer, 2007
- Caring for survivors of childhood cancers: The size of the problemEuropean Journal of Cancer, 2006
- The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2004
- Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by DoxorubicinJournal of Clinical Oncology, 1999
- Early identification of anthracycline cardiomyopathy: possibilities and implications.Archives of Disease in Childhood, 1996
- Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effectsCancer, 1992
- ELEVATION OF LIPID PEROXIDE IN CHILDREN TREATED WITH A COMBINATION OF CHEMOTHERAPEUTIC AGENTS INCLUDING DOXORUBICINActa Paediatrica, 1983
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- CARDIAC TOXICITY OF DAUNORUBICINThe Lancet, 1969